Annual report
9265.TEDINET S100U91I
Period2023-06-01 → 2024-05-31
Filed2024-08-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥61.6bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥58.2bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥70.1bn | 2020-06-01 → 2021-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥64.7bn | 2019-06-01 → 2020-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥967m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | ¥1.2bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2020-06-01 → 2021-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥642m | 2019-06-01 → 2020-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥871m | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥635m | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥580m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥678m | 2020-06-01 → 2021-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥459m | 2019-06-01 → 2020-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥577m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | ¥211m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥26.6bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥24.1bn | at 2022-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.3bn | at 2021-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥21.4bn | at 2020-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.0bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥16.6bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-05-31d | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2021-05-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.9bn | at 2020-05-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.3bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.3bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2021-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.0bn | at 2020-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥878m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.2bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥581m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥911m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥817m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥107m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥134m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥33m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥335m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥209m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥229m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥137m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥107m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥227.96 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.83 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥265.77 | 2020-06-01 → 2021-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥180.07 | 2019-06-01 → 2020-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,429.08 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,097.34 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,126.18 | at 2022-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,969.03 | at 2021-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,717.81 | at 2020-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 32.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.2% | at 2021-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.4% | at 2020-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2023-06-01 → 2024-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2022-06-01 → 2023-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-06-01 → 2022-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2020-06-01 → 2021-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-06-01 → 2020-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 606 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 570 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 574 | at 2022-05-31d | Cons. | Number of employees |
| Employees | 553 | at 2021-05-31d | Cons. | Number of employees |
| Employees | 551 | at 2020-05-31d | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2023-06-01 → 2024-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥498m | 2022-06-01 → 2023-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥792m | 2021-06-01 → 2022-05-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥854m | 2020-06-01 → 2021-05-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥508m | 2019-06-01 → 2020-05-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥763m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Operating income | −¥16m | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Ordinary income | ¥764m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥16m | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥227m | 2021-06-01 → 2022-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥347m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥136m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥764m | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Profit before tax | −¥16m | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Net income | ¥767m | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | −¥13m | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥228m | 2021-06-01 → 2022-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥348m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥100m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.0bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥6.3bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥6.5bn | at 2022-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.4bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.0bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.8bn | at 2024-05-31 | Standalone | Liabilities |
| Total liabilities | ¥489m | at 2023-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.3bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2022-05-31d | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥5.8bn | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥312m | at 2024-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥175m | at 2023-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥301.31 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.29 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.32 | 2021-06-01 → 2022-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.46 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.38 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2022-06-01 → 2023-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥82 | 2021-06-01 → 2022-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2020-06-01 → 2021-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,521.27 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,272.88 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.07 | at 2022-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.75 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,278.24 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 78.2% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.2% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.4% | at 2022-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.9% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.7% | 2023-06-01 → 2024-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.2% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-06-01 → 2022-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,553,000 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2022-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 29 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 30 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 27 | at 2022-05-31d | Standalone | Number of employees |
| Employees | 24 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 20 | at 2020-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2023-06-01 → 2024-05-31 | ¥27m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-05-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-05-31 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥1.2bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥2m |
| Medical Equipment Manufacturing And Salesreportable segment | employees | at 2024-05-31 | 5 pure |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥267m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥267m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥1m |
| Medical Equipment Salesreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥138m |
| Medical Equipment Salesreportable segment | employees | at 2024-05-31 | 556 pure |
| Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥61.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥61.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥2.2bn |
| Medical Mallreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥16m |
| Medical Mallreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥68m |
| Medical Mallreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥68m |
| Medical Mallreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥0 |
| —segment total | depreciation | 2023-06-01 → 2024-05-31 | ¥157m |
| —segment total | revenue | 2023-06-01 → 2024-05-31 | ¥61.6bn |
| —segment total | revenue external | 2023-06-01 → 2024-05-31 | ¥61.6bn |
| —segment total | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥1m |
| —segment total | segment profit | 2023-06-01 → 2024-05-31 | ¥2.2bn |
| Reconciling Itemsreconciling | depreciation | 2022-06-01 → 2023-05-31 | ¥31m |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-05-31 | −¥12m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-05-31 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥1.0bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥4m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥286m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥286m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥12m |
| Medical Equipment Salesreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥137m |
| Medical Equipment Salesreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥57.9bn |
| Medical Equipment Salesreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥57.8bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥11m |
| Medical Equipment Salesreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥2.1bn |
| Medical Mallreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥16m |
| Medical Mallreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥69m |
| Medical Mallreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥69m |
| Medical Mallreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥0 |
| —segment total | depreciation | 2022-06-01 → 2023-05-31 | ¥157m |
| —segment total | revenue | 2022-06-01 → 2023-05-31 | ¥58.2bn |
| —segment total | revenue external | 2022-06-01 → 2023-05-31 | ¥58.2bn |
| —segment total | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥12m |
| —segment total | segment profit | 2022-06-01 → 2023-05-31 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,415
| Item | Context | Value | Unit |
|---|---|---|---|
| Total changes of items during the period | CurrentYearDuration_ValuationAndTranslationAdjustmentsMember | 343000000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonControllingInterestsMember | -3000000 | JPY |
| Total changes of items during the period | CurrentYearDuration | 632000000 | JPY |
| Net assets | CurrentYearInstant_CapitalStockMember | 494000000 | JPY |
| Net assets | CurrentYearInstant_CapitalSurplusMember | 627000000 | JPY |
| Net assets | CurrentYearInstant_RetainedEarningsMember | 6763000000 | JPY |
| Net assets | CurrentYearInstant_TreasuryStockMember | -165000000 | JPY |
| Net assets | CurrentYearInstant_ShareholdersEquityMember | 7720000000 | JPY |
| Net assets | CurrentYearInstant_ValuationDifferenceOnAvailableForSaleSecuritiesMember | 715000000 | JPY |
| Net assets | CurrentYearInstant_RemeasurementsOfDefinedBenefitPlansMember | 107000000 | JPY |
| Net assets | CurrentYearInstant_ValuationAndTranslationAdjustmentsMember | 822000000 | JPY |
| Net assets | CurrentYearInstant_NonControllingInterestsMember | 14000000 | JPY |
| Net assets | CurrentYearInstant | 8556000000 | JPY |
| Income before income taxes | Prior1YearDuration | 635000000 | JPY |
| Income before income taxes | CurrentYearDuration | 871000000 | JPY |
| Depreciation and amortization ope cf | Prior1YearDuration | 189000000 | JPY |
| Depreciation and amortization ope cf | CurrentYearDuration | 185000000 | JPY |
| Amortization of goodwill ope cf | Prior1YearDuration | 14000000 | JPY |
| Amortization of goodwill ope cf | CurrentYearDuration | 28000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YearDuration | 609000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYearDuration | -14000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YearDuration | 57000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYearDuration | 7000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YearDuration | 2000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYearDuration | 20000000 | JPY |
| Interest and dividends income ope cf | Prior1YearDuration | -9000000 | JPY |
| Interest and dividends income ope cf | CurrentYearDuration | -10000000 | JPY |
| Interest expenses ope cf | Prior1YearDuration | 2000000 | JPY |
| Interest expenses ope cf | CurrentYearDuration | 0 | JPY |
| Receipts from contingent consideration ope cf | Prior1YearDuration | -6000000 | JPY |
| Receipts from contingent consideration ope cf | CurrentYearDuration | － | JPY |
| Loss gain on sales of investment securities ope cf | Prior1YearDuration | -33000000 | JPY |
| Loss gain on sales of investment securities ope cf | CurrentYearDuration | － | JPY |
| Impairment loss ope cf | Prior1YearDuration | － | JPY |
| Impairment loss ope cf | CurrentYearDuration | 200000000 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YearDuration | 7000000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYearDuration | 6000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YearDuration | 1414000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYearDuration | -439000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YearDuration | -205000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | -46000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YearDuration | 577000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | 603000000 | JPY |
| Decrease increase in claims provable in bankruptcy claims provable in rehabilitation ope cf | Prior1YearDuration | -610000000 | JPY |
| Decrease increase in claims provable in bankruptcy claims provable in rehabilitation ope cf | CurrentYearDuration | 15000000 | JPY |
| Other net ope cf | Prior1YearDuration | -243000000 | JPY |
| Other net ope cf | CurrentYearDuration | 23000000 | JPY |
| Subtotal ope cf | Prior1YearDuration | 2400000000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 1451000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YearDuration | 9000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |